CSIMarket
 


Genetic Technologies Limited  (GENE)
Other Ticker:  
 
 

GENE's EPS from Cont. Operations Growth by Quarter and Year

Genetic Technologies Limited's EPS from Cont. Operations results by quarter and year




GENE EPS from Cont. Operations (in $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.00 0.00 0.00 0.00
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   0.00 0.00 0.00 0.00



GENE EPS from Cont. Operations fourth quarter 2022 Y/Y Growth Comment
Genetic Technologies Limited in the fourth quarter 2022 recorded EPS loss from Cont. Operations of $ 0.00 .

According to the results reported in the fourth quarter 2022, Genetic Technologies Limited achieved the best EPS from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Genetic Technologies Limited' s EPS from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2022.




GENE EPS from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Genetic Technologies Limited's fourth quarter 2022 EPS from Cont. Operations $ 0.00 GENE's Income Statement
Genetic Technologies Limited's fourth quarter 2021 EPS from Cont. Operations $ 0.00 Quarterly GENE's Income Statement
New: More GENE's historic EPS from Cont. Operations Growth >>


GENE EPS from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




EPS from Cont. Operations fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS from Cont. Operations fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genetic Technologies Limited's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GENE's IV. Quarter Q/Q EPS from Cont. Operations Comment


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GENE's IV. Quarter Q/Q EPS from Cont. Operations Comment


Genetic Technologies Limited's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2019)
12 Months Ending
0
12 Months Ending
(Jun 30 2018)
12 Months Ending
0
12 Months Ending
0
Cumulative EPS from Cont. Operations 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y EPS from Cont. Operations Growth (TTM) - - - - -
Year on Year EPS from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential EPS from Cont. Operations Change (TTM) - - - - -
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative EPS from Cont. Operations growth Comment
In the Jun 30 2019 period, Genetic Technologies Limited's cumulative trailing twelve month EPS from Cont. Operations remained unchanged compare to the same period a year ago.

Genetic Technologies Limited achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS from Cont. Operations growth Comment
In the Jun 30 2019 period, Genetic Technologies Limited's cumulative trailing twelve month EPS from Cont. Operations remained unchanged compare to the same period a year ago.

Genetic Technologies Limited achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
GENE's EPS from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for GENE's Competitors
EPS from Cont. Operations Growth for Genetic Technologies Limited's Suppliers
EPS from Cont. Operations Growth for GENE's Customers

You may also want to know
GENE's Annual Growth Rates GENE's Profitability Ratios GENE's Asset Turnover Ratio GENE's Dividend Growth
GENE's Roe GENE's Valuation Ratios GENE's Financial Strength Ratios GENE's Dividend Payout Ratio
GENE's Roa GENE's Inventory Turnover Ratio GENE's Growth Rates GENE's Dividend Comparisons



Companies with similar EPS from Cont. Operations no change for the quarter ending Jun 30 2019 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Jun 30 2019
Amedisys Inc -0.19%$ -0.193 
Zoetis Inc -3.12%$ -3.123 
Bruker Corporation-4.38%$ -4.377 
Conmed Corporation-4.88%$ -4.876 
Amgen Inc -5.68%$ -5.682 
Novartis Ag-5.88%$ -5.882 
Revvity Inc -9.38%$ -9.375 
Vascular Biogenics Ltd -12.90%$ -12.903 
Fonar Corporation-14.29%$ -14.286 
Tandem Diabetes Care Inc -17.46%$ -17.457 
Acorda Therapeutics Inc -17.65%$ -17.654 
United Therapeutics Corporation-19.08%$ -19.081 
Regeneron Pharmaceuticals Inc -19.53%$ -19.531 
Phibro Animal Health Corporation-21.62%$ -21.622 
Cyclacel Pharmaceuticals Inc -21.74%$ -21.739 
Lantheus Holdings Inc -22.96%$ -22.955 
Purple Biotech Ltd -23.08%$ -23.077 
National Healthcare Corp-24.35%$ -24.355 
U S Physical Therapy Inc-24.35%$ -24.355 
Lemaitre Vascular Inc -25.20%$ -25.203 
Antares Pharma Inc -26.07%$ -26.067 
3m Company-26.89%$ -26.895 
Trillium Therapeutics Inc -29.61%$ -29.606 
Fresenius Medical Care Ag-31.45%$ -31.450 
Catalent Inc -32.35%$ -32.353 
Check cap Ltd -33.72%$ -33.716 
Sanofi-35.07%$ -35.072 
American Shared Hospital Services-36.64%$ -36.644 
Enovis Corporation-36.86%$ -36.859 
Align Technology inc -37.21%$ -37.209 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com